Until recently, to block PCSK9 was to utilize an injection. That changed in July 2026, when the FDA approved Lipfendra — the first PCSK9 inhibitor to become available in pill form.
Lipfendra contains enlicitide and is taken as a single daily dose. It has been approved, in conjunction with diet and exercise, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (a genetic syndrome that may lead to extremely high levels of cholesterol from a young age).
The new drug presents another option for individuals seeking a significant reduction in LDL but wishing to avoid injectables.
How does Lipfendra work?
The liver clears bad cholesterol (LDL) from the bloodstream using specialized receptors on its surface.
PCSK9 is a protein that causes some of these receptors to be destroyed, reducing the number available to remove LDL from circulation.
By binding to PCSK9, Lipfendra prevents it from interacting with the LDL receptor, thus preserving receptor availability and enabling the liver to remove more LDL.
Lipfendra is mechanistically analogous to the injectable PCSK9 inhibitors Repatha and Praluent. The difference lies in its formulation as an oral tablet.
How much can it reduce LDL?
The FDA approval was largely based upon two Phase 3 trials, CORALreef Lipids and CORALreef HeFH.
In the former, 2,904 adults with hypercholesterolemia who required additional therapy were given either Lipfendra or a placebo along with continued lipid-lowering treatment. The reduction in LDL seen after 24 weeks of treatment was 56 percent placebo-adjusted.
In the latter, a 303-patient trial focused on individuals with familial hypercholesterolemia, the mean placebo-adjusted reduction in LDL was 59 percent.
These are sizable reductions, and represent drops of approximately half of baseline levels (for an individual beginning treatment with an LDL of 120 mg/dL). However, responses are variable, and results should be interpreted individually.
A reduction can be seen as early as four weeks after commencing treatment.
Does it replace statins?
Not necessarily.
Statins are considered first-line therapy for reducing LDL levels, due to their consistent LDL-lowering efficacy as well as substantial evidence of reduced risk of cardiovascular events. In fact, 97 percent of subjects in the main trial for Lipfendra were already using a statin in addition to the investigational drug.
Lipfendra may be considered when treatment with other agents is inadequate, or another therapeutic option is desired. The decision to use it would be based upon cardiovascular risk, treatment history, tolerance, insurance coverage and the magnitude of additional LDL reduction required.
It should be noted that patients considering their options in terms of cardioprotective drugs should not simply discontinue a statin just because a new pill has become available.
How is it taken?
The recommended dose is one 20 mg tablet each morning.
This must be taken on an empty stomach, with water, black coffee or plain tea. The tablet should be swallowed whole.
At least 30 minutes should elapse between taking the medication and eating or drinking anything other than water, black coffee or plain tea.
Food is an important consideration when taking Lipfendra, as taking it after a meal can reduce bioavailability.
If a dose is missed, it can be taken later in the day — as long as it is at least 30 minutes before the next meal or drink. Two doses should not be taken on the same day.
What are the side effects?
In the large trial for patients with hypercholesterolemia, adverse-reaction rates were similar between the treatment and placebo groups.
The most common adverse reactions reported among patients with heterozygous familial hypercholesterolemia were dizziness and diarrhea, which occurred more frequently in the Lipfendra group (9 percent and 7 percent, respectively) than in the placebo group (4 percent and 2 percent).
Lipfendra does not have any contraindications listed in its initial prescribing information, but it is not suitable for everyone.
In general, treatment should be discontinued when pregnancy is suspected, unless the potential benefit justifies the risk to the fetus. Its safety and efficacy have not been established in pediatrics.
Does it prevent heart attacks?
Lowering LDL is associated with reduced cardiovascular risk, and both statins and injectable PCSK9 inhibitors have been shown to reduce the likelihood of cardiovascular events occurring.
Lipfendra itself has not demonstrated that it reduces the risk of heart attack or stroke — its FDA approval was based solely upon its ability to decrease LDL levels. The ongoing CORALreef Outcomes trial is evaluating this exact question.
It is important to note this difference, in order to understand that while the reduction in cholesterol is proven, the drug-specific cardioprotection has yet to be demonstrated.
Lipfendra represents an opportunity for people who wish to receive PCSK9 inhibition without the inconvenience of periodic injections. Whether it becomes a staple in the treatment armamentarium depends on cost, insurance coverage, long-term follow-up and the results of its cardiovascular outcomes trial.
